ArticleComputerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society2026
A deep learning-based automated pipeline for colorectal cancer detection in contrast-enhanced CT images.
Article in Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Attention-Enhanced ResNet-U-Net for Automated Colorectal Tumor Segmentation in CT Scans.Life (Basel, Switzerland) · 2026Article
- The Diagnostic Value of Deep Learning for Multi-Classification of Rectal Cancer T Staging Based on Regional Attention.Diagnostics (Basel, Switzerland) · 2026Article
- Artificial intelligence in colorectal cancer multidisciplinary decision-making: concordance, predictive support and clinical translation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and a leading cause of cancer-related mortality. This study aims to investigate an automatic detection pipeline for identification and localization of the primary CRC in portal venous phase contrast-enhanced CT scans, which is a crucial first step for downstream CRC staging, prognostication, and treatment planning. We propose a deep learning-based automated detection pipeline using YOLOv11 as the baseline architecture. A ResNet50 module was incorporated into the YOLOv11 backbone to enhance image feature extraction. Additionally, a scale-adaptive loss function, which introduces an adaptive coefficient and a scaling factor to adaptively measure the Intersection over Union (IoU) and center point distance for improving box regression performance, was designed to further improve detection performance. The proposed pipeline achieved a recall of 0.8092, precision of 0.8187, and F-1 score of 0.8139 for CRC detection on our in-house dataset at the patient level (inter-patient evaluation) and a recall of 0.9949, precision of 0.9894, and F-1 score of 0.9921 at the slice level (intra-patient evaluation). Validation on an external public dataset demonstrated that our pipeline, when trained on a patient-level in-house dataset, obtained a recall of 0.8283, precision of 0.8414, and F-1 score of 0.8348 and, when trained on a slice-level in-house dataset, achieved a recall of 0.6897, precision of 0.7888, and F-1 score of 0.7358, outperforming existing representative detection methods. The superior CRC detection performance on the in-house CT dataset and state-of-the-art generalization performance on the public dataset (with a 31.97 %age point improvement in detection sensitivity (recall) over the next closest state-of-the-art method), highlight the potential translational value of our pipeline for CRC clinical decision support, conditional upon validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.